The rapid evolution of CRISPR/Cas genome editing has redefined the possibilities of cellular and gene therapy, enabling ...

Recent commentary has highlighted CRISPR Therapeutics’ expanding gene-editing pipeline, including cardiovascular candidates like CTX310 and CTX320 and programs in type 1 diabetes, alongside fresh Buy ...

Detailed price information for Editas Medicine (EDIT-Q) from The Globe and Mail including charting and trades.

Cas13a consists of two lobes—the recognition (REC) and nuclease (NUC) domains—and is guided by a crRNA (50–58 nt) comprising a direct repeat sequence followed by a spacer region. Under the canonical ...

Wondering if CRISPR Therapeutics at around US$51.22 is pricing in too much hope or leaving room on the table? This article walks through what the current share price may be implying about the company.

Despite a lackluster launch, CASGEVY has significant potential in international markets, bolstering CRISPR's long-term value. Upcoming milestones and updates on CRISPR Therapeutics is currently ...

The rapid evolution of CRISPR/Cas genome editing has redefined the possibilities of cellular and gene therapy, enabling precise correction, ...

CRISPR Therapeutics has an approved gene-therapy treatment still in its early growth stages. The company isn't profitable, but has a strong cash position, which can help buy a lot of time. One of the ...

Colossal Biosciences is establishing standards for how biotechnology can responsibly support biodiversity conservation in an ...